Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro

Leukemia

Volumn 16, Issue 11, 2002, Pages 2285-2291

  Pathak, M K ^a   Hu, X ^c   Yi, T ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

AML; Differentiation; Leukemia; PTPase inhibitor; Sodium stibogluconate

Indexed keywords

CD11B ANTIGEN; CELL PROTEIN; IMATINIB; NITROBLUE TETRAZOLIUM; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID; STIBOGLUCONATE SODIUM;

ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EXPOSURE; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0036848182     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402692     Document Type: Article

References (44)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med, 1985; 103: 460-462.
3. Bloomfield CD, Brunning RD. The revised French-American-British classification of acute myeloid leukemia: is new better? Ann Intern Med 1985; 103: 614-616.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Calton DA, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325-329.
5. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1987; 90: 2863-2892.
6. Kogan SC, Bishop JM. Acute promyelocytic leukemia: from treatment to genetics and back. Oncogene 1999; 18: 5261-5267.
7. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
8. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Francois C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 1999; 95: 90-95.
9. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
10. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene, 1999; 18: 5278-5292.
11. Metcalf D. Cellular hematopoiesis in the twentieth century. Semin Hematol 1999; 36: 5-12.
12. Salem M, Delwel R, Mahmoud LA, Clark S, Elbasousy EM, Lowenberg, B. Maturation of human acute myeloid leukaemia in vitro: The response to five recombinant haematopoietic factors in a serum-free system. Br J Haematol 1989; 71: 363-370.
13. Bergamaschi G, Carlo-Stella C, Cazzola M, De Fazio P, Pedrazzoli P, Peverali FA, Della Valle G. Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. Leukemia 1990; 4: 426-430.
14. Core SD, Weng LJ, Jones RJ, Cowan K, Zilcha M, Piantadosi S, Burke PJ. Impact of in vivo administration of interleukin 3 on pro-liferation, differentiation, and chemosensitivity of acute myeloid leukemia. Clin Cancer Res, 1995; 1: 295-303.
15. Hirai H, Shimazaki C, Yamagata N, Goto H, Inaba T, Kikuta T, Sumikuma T, Sudo Y, Ashihara E, Fujita N, Hibi S, Imashuku S, Ito E, Nakagawa M. Effects of thrombopoietin (c-mpl ligand) on growth of blast cells from patients with transient abnormal myelopoiesis and acute myeloblastic leukemia. Eur J Haematol 1997; 59: 38-46.
16. Chen GQ Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, MaJ Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
17. Frank DA, Sartorelli AC. Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells. Cancer Res 1988; 48: 52-58.
18. Zanke B, Squire J, Griesser H, Henry M, Suzuki H, Patterson B, Minden M, Mak TW. A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia 1994; 8: 236-244.
19. Zhao Z, Shen SH, Fischer EH. Phorbol ester-induced expression, phosphorylation, and translocation of protein-tyrosine-phosphatase 1C in HL-60 cells. Proc Natl Acad Sci USA 1994; 91: 5007-5011.
20. Bittorf T, Seiler J, Zhang Z, Jaster R, Brock J. SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem 1999; 380: 1201-1209.
21. Gianni M, Kalac Y, Ponzanelli I, Rambaldi A, Terao M, Garattini E. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. Blood 2001; 97: 3234-3243.
22. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 1988; 10: 560-586.
23. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis 1980; 142: 83-86.
24. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83: 1253-1257.
25. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hematopoietic cell lines. Immunol 2001; 167: 3391-3397.
26. Thomassen MJ, Yi T, Raychaudhuri B, Malur A, Kavuru MS. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95: 85-92.
27. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
28. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-733.
29. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer, 1976; 17: 565-577.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
31. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 1979; 149: 969-974.
32. Idres N, Benoit G, Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Cancer Res 2001; 61: 700-705.
33. James SY, Williams MA, Kelsey SM, Newland AC, Colston KW. Interaction of vitamin D derivatives and granulocyte-macrophage colony-stimulating factor in leukaemic cell differentiation. Leukemia 1997; 11: 1017-1025.
34. Hsu HC, Tsai WH, Hsu ML, Ho CH, Wang SY. Effects of colony-stimulating factors on the all-trans retinoic acid-induced differentiation of acute promyelocytic leukemic cells. Chung Hua I Hsueh Tsa Chih 1996; 57: 93-99.
35. Drexler HG. The Leukemia-Lymphoma Cell Line Facts Book. Academic Press: San Diego, 2000.
36. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller W Jr. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88: 2826-2832.
37. Hooft van Huijscluijnen R. Protein tyrosine phosphatases: counting the trees in the forest. Gene 1998; 225: 1-8.
38. Yi T, Cleveland JL, Ihle JN. Identification of novel protein tyrosine phosphatases of hematopoietic cells by polymerase chain reaction amplification. Blood 1991; 78: 2222-2228.
39. Jiao H, Yang W, Berrada K, Tibrizi M, Shultz L, Yi T. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative response to GM-CSF: detection of potential HCP substrates in GM-CSF signal transcluction. Exp Hematol 1997; 25: 592-600.
40. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, Thomas ML. and Beier DR. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993; 73: 1445-1454.
41. Herwaldt BL, Kaye ET, Lepore TJ, Berman JD, Baden HP. Sodium stibogluconate (Pentostam) overdose during treatment of American cutaneous leishmaniasis. J Infect Dis 1992; 165: 968-971.
42. Gianni M, Terao M, Zanotta S, Barbui T, Rambaldi A, Garattini E. Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. Blood 1994; 83: 1909-1921.
43. Gianni M, Zanotta S, Terao M, Rambaldi, A, Garattini E. Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: potentiation of the induction of retinoid-dependent differentiation markers. Int J Cancer 1996; 68: 75-83.
44. Stark GR. Genetic analysis of interferon and other mammalian signaling pathways. Harvey Lect 1997; 93: 1-16.